ArticleResearch and practice in thrombosis and haemostasis2025
Longitudinal dynamics of hemostatic biomarkers in patients with cancer receiving immune checkpoint inhibitors vs chemotherapy: results from the Vienna CAT-BLED study.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Antiphospholipid antibody formation during immune checkpoint inhibition in patients with cancer: a prospective cohort study.Research and practice in thrombosis and haemostasis · 2026Article
- Cancer-Associated Thrombosis in Patients Treated with Immune Checkpoint Inhibitors.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Venous thromboembolism is a common cause of morbidity and mortality in patients with cancer, with chemotherapy being an established risk factor. Emerging data suggest elevated venous thromboembolism risk with immune checkpoint inhibitors (ICIs), yet the association between ICIs and hypercoagulability remains unclear. Objectives: We aimed to evaluate longitudinal levels of hemostatic biomarkers in patients during chemotherapy and ICI monotherapy. Methods: Patients were matched by age, sex, cancer type, and stage. Biomarker levels were measured at baseline, 3 weeks and 3 months after treatment and compared using Wilcoxon rank-sum tests with a mixed-effects model used to assess the effects of therapy and time. Spearman's correlation analyzed biomarker relationships. Results: Thirty patients (20 with non-small cell lung cancer and 10 with head and neck cancer) were included. Eighteen patients (60%) were females, with a median age of 66 years (IQR, 57-78). Levels of soluble P-selectin, D-dimer, extracellular vesicle tissue factor activity, peak thrombin, and neutrophil extracellular trap formation (via citrullinated histone H3 in complex with extracellular DNA) showed an increasing tendency over time, with comparable biomarker levels between treatment modalities. Mixed-effects analysis revealed weak differences in the longitudinal dynamics of biomarker levels within the first 3 months of treatment, with ICI therapy (compared with chemotherapy) being associated with higher levels of soluble P-selectin (+3.03 ng/mL; Conclusion: Hemostatic biomarker levels were largely comparable between the 2 treatment modalities and showed increasing trends over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.